Tandem Diabetes Care Inc
Suletud
SektorTervishoid
16.18 -3.11
Ülevaade
Aktsiahinna muutus
24h
Min
16.18
Max
16.98
Sissetulek | -775K -21M |
|---|---|
Müük | 7.3M 255M |
Aktsiakasum | -0.31 |
Kasumimarginaal | -8.316 |
Töötajad | 2,500 |
EBITDA | 4.5M -9.2M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +57.43% upside |
Järgmine tulemuste avaldamine | 5. nov 2026 |
|---|
Turukapital | 6.5M 1.4B |
|---|---|
Eelmine avamishind | 19.29 |
Eelmine sulgemishind | 16.18 |
Tandem Diabetes Care Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Tandem Diabetes Care Inc Prognoos
Hinnasiht
By TipRanks
57.43% tõus
12 kuu keskmine prognoos
Keskmine 26.464 USD 57.43%
Kõrge 50 USD
Madal 15.5 USD
Põhineb 15 Wall Streeti analüütiku instrumendi Tandem Diabetes Care Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.